Speciality Medicines IPO
Bookbuilding IPO | ₹29.00 Cr | Listing at BSE SME
Closed
IPO Open
Fri, Mar 20, 2026
IPO Close
Tue, Mar 24, 2026
Price Band
₹117.00 to ₹124.00
Market Cap (Pre-IPO)
-
IPO Details
| IPO Date | Mar 20, 2026 to Mar 24, 2026 |
| Listing Date | Tentative: Mar 30, 2026 |
| Face Value | ₹10.00 per share |
| Price Band | ₹117.00 to ₹124.00 |
| Lot Size | 1000 Shares (Minimum: ₹124,000.00) |
| Sale Type | Fresh Issue |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Issue Size | ₹29.00 Crores |
| Total Shares Offered | 2,350,000 shares |
| Offer For Sale | 2,350,000 shares |
Speciality Medicines IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 2% of the Net Issue |
| Retail Shares Offered | Not less than 49% of Net Issue |
| NII Shares Offered | Not less than 49% of Net Issue |
Speciality Medicines IPO Lot Size
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | ₹248,000 |
| Retail (Max) | 2 | 2,000 | ₹248,000 |
| S-HNI (Min) | 3 | 3,000 | ₹372,000 |
| S-HNI (Max) | 8 | 8,000 | ₹992,000 |
| B-HNI (Min) | 9 | 9,000 | ₹1,116,000 |
Speciality Medicines Financial Information (Restated Consolidated)
| Period Ended | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 26.44 | 23.43 | 13.26 | 5.78 |
| Total Income | 8.37 | 27.66 | 23.26 | 40.45 |
| Profit After Tax | 2.30 | 4.55 | 1.69 | 1.48 |
| EBITDA | - | - | - | - |
| NET Worth | 19.23 | 16.61 | 5.87 | 1.93 |
| Reserves and Surplus | 14.08 | 11.50 | 2.05 | 1.72 |
| Total Borrowing | 2.53 | 2.86 | 3.64 | 1.18 |
Amount in ₹ Cr
Key Performance Indicators
As of Sunday, March 31, 2024| KPI | Values |
|---|---|
| ROE (Return on Equity) | 40.44% |
| ROCE (Return on Capital Employed) | 34.95% |
| Debt/Equity | 0.17 |
| RoNW (Return on Net Worth) | 27.36% |
| PAT Margin (Profit After Tax Margin) | 16.52% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 7.06 | 15.79 |
| P/E (x) | 59.28 | 43.44 |
Company Promoters
- Parth B Goyani and Goyani Sumit Babubhai are the company promoters.
Company Overview
Speciality Medicines – Company Overview
- Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of speciality pharmaceutical formulations, including high-cost oral and injectable medicines used for complex chronic diseases.
- The company offers a wide range of dosage forms such as tablets, capsules, syrups, injections, inhalers, gels, ointments, eye drops, and more, catering to diverse medical needs.
Business Model
- Contract Manufacturing: Manufacturing finished formulations for international markets.
- Marketing & Distribution: Selling sourced speciality pharma products across domestic and global markets.
- The company has a presence across 20+ states in India and 35+ countries globally, including markets like Jordan, Ethiopia, Uganda, Peru, and Namibia.
- As of March 31, 2025, the company had 1 product registered overseas and 60 products under registration across multiple countries.
- As of August 31, 2025, the company had 18 permanent employees.
Use of Proceeds
| 1) | Setting up of Research and Development (R&D) Center | 13.31 |
| 2) | Product registration in the international markets | 2.89 |
| 3) | Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company | 1.75 |
| 4) | To Meet Working Capital Requirements | 12.00 |
| 5) | General Corporate Purpose |
Objectives
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Speciality Medicines IPO Peer Comparison
Speciality Medicines peer comparison with similar listed entities. (As on March 31, 2025)| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Speciality Medicines Ltd. | 14.10 | 14.10 | 47.26 | 8.79 | 28.42 | - | - |
| Remus Pharmaceuticals Ltd. | 65.21 | 65.21 | 434.25 | 10.41 | 15.02 | - | - |
| Trident Lifeline Ltd. | 10.22 | 10.22 | 56.05 | 27.00 | 18.23 | - | - |
| Mono Pharmacare Ltd. | 1.75 | 1.75 | 17.66 | 7.49 | 9.90 | - | - |
Quick Info
| Sector | Pharmaceuticals & Drugs |
| Exchange | BSE SME |
Important Dates
| IPO Open | Mar 20, 2026 |
| IPO Close | Mar 24, 2026 |
| Allotment Date | Mar 25, 2026 |
| Credit to Demat | Mar 27, 2026 |
| Listing Date | Tentative: Mar 30, 2026 |
Lead Manager(s)
Unicon Capital Services Pvt.Ltd.
Registrar
Skyline Financial Services Pvt.Ltd.
02228511022
Description
- IPO Type: Book build issue aggregating to ₹29.14 crores.
- Issue Structure: Entirely a fresh issue of 0.24 crore shares totaling ₹29.14 crores.
- IPO Dates: The issue opens on March 20, 2026 and closes on March 24, 2026.
- Allotment Date: Expected to be finalized on March 25, 2026.
- Listing Details: Shares are proposed to be listed on the SME platform of BSE Limited (BSE SME) with a tentative listing date of March 30, 2026.
- Retail Investment Requirement: Minimum 2 lots (2,000 shares) amounting to approximately ₹2,48,000 at the upper price band.
- HNI Investment Requirement: Minimum 3 lots (3,000 shares) totaling around ₹3,72,000.
- IPO Price Band: ₹117 to ₹124 per equity share.
- Lot Size: 1,000 shares per lot.
This IPO offers investors an opportunity to participate in the pharmaceutical sector, subject to market risks.